G. Schwartz’s research while affiliated with University of Texas Health Science Center at Tyler and other places

... No responses were seen in seven patients with advanced CRC enrolled in a Phase I trial of lapatinib in combination with capecitabine. 52 Phase I studies conducted in patients with advanced solid malignancies revealed no dose-limiting toxicities when lapatinib was combined with FOLFOX4, but dose-limiting toxicities of diarrhea and myelosuppression were seen when lapatinib was combined with FOLFIRI. ...

Reference:

EGFR-Targeted Therapies in Colorectal Cancer

... 11,12 Data in the neoadjuvant setting suggest that lapatinib may inhibit the self-renewal of HER2-overexpressing breast cancer stem cells, rendering them more sensitive to cytotoxic chemotherapy. 13 Based on positive efficacy and safety data from singleagent phase I and II clinical studies, [14][15][16][17] a randomized, double-blind, comparative trial of lapatinib plus capecitabine versus capecitabine alone was initiated in patients with HER2-positive, trastuzumab-resistant MBC. 18 As this trial (EGF100151) formed the basis for global regulatory approvals of lapatinib, it is pertinent to consider key inclusion and exclusion criteria. ...

Reference:

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2‐positive breast cancer

... There are several alternatives to PEG-conjugated anticancer agents. Paclitaxel poliglumex (PPX, Xyotax, Cell Therapeutics, Seattle, WA), a macromolecular drug conjugate that links paclitaxel with a biodegradable polymer, poly-L-glutamic acid, has completed phase I studies [99]. PPX is a water-soluble formulation that also eliminates the need for polyethoxylated castor oil in the formulation. ...

Reference:

Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents

... The combination was well tolerated. Intriguingly, responses were seen in patients with taxane and trastuzumab refractory breast cancer, indicating that EGFR inhibition may overcome resistance to trastuzumab therapy (41). ...

Reference:

Her2-Targeted Therapies in Non-Small Cell Lung Cancer

... Tasidotin (ILX-651), an orally active synthetic microtubule-targeted derivative of the marine depsipeptide dolastatin-15, is currently undergoing clinical evaluation for cancer treatment. Phase-I trials with ILX651, in patients with advanced solid tumors, indicated that the compound is well tolerated and no cardiotoxicities were observed, as observed with the compound LU-103793 (Mita et al., 2006). Tasidotin has completed three rounds of clinical tests II in patients with hormone refractory prostate cancer and advanced or metastatic non-small-lung carcinoma (Tan, 2010). ...

Reference:

Recent developments in therapeutic applications of Cyanobacteria

... Dovepress Dovepress therapy, and in a Phase I study in combination with an anti-HER-2/neu-targeted agent trastuzumab. 89 In 2003, Johnston et al published the results of a single-agent tipifarnib study that compared two cohorts of advanced BC patients treated with either continuous dosing (CD, n = 41) of tipifarnib 400 or 300 mg BID or intermittent dosing (ID, n = 35) of 300 mg BID for 21 days every 4 weeks. 57 In the CD cohort, 10% had a partial response and 15% had stable disease at or beyond 24 weeks, whereas in the ID cohort, 14% had a partial response and 9% had stable disease. ...

Reference:

Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review

... Several phase I studies evaluated different infusion schedules of trabectedin in solid tumors, yielding objective antitumor response in heavily pretreated patients affected by bone sarcoma, melanoma, mesothelioma, and breast and ovarian cancer [24][25][26][27]. The recommended phase II doses were 1.5 mg/m 2 as a 24-h continuous infusion every 3 weeks and 0.58 mg/m 2 as a 3-h infusion weekly for 3 out of 4 weeks [24,26]. ...

Reference:

Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma

... Panitumumab gained FDAapproval in 2006 for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with disease progression while on or following fluoropyrimidine-, oxaliplatin-, or irinotecan-containing chemotherapy regimens [22]. Panitumumab has been well tolerated in clinical trials and as a result, close observation of patients has not been required nor has pre-medication with antihistamines [23]. The intact antibody has been shown to be successfully radiolabeled with 111 In in high yields and has demonstrated excellent tumor targeting with low normal tissue uptake [24,25]. ...

Reference:

In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers

... Recently, the results of the BR.21 Phase III study showed a significant 42.5% improvement in median survival compared to placebo in patients with advanced NSCLC [16] and the US Food and Drug Administration (FDA) has approved erlotinib for this indication in November 2004. Moreover, phase I clinical trials of erlotinib plus paclitaxel-carboplatin [17], or gemcitabine-cisplatin [18], or docetaxel [19] have been undertaken. Concomitant pharmacokinetic studies [18,19] revealed that no interactions occurred between the tested cytostatics and erlotinib, thus facilitating combination treatments with full doses of cytostatics. ...

Reference:

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics

... Several drugs targeting metalloproteinases (MMPs) have been developed to control CSC invasion and metastasis (Roma-Rodrigues et al. 2019). For instance, incyclinide, also known as CMT-3 or COL-3, is an MMP inhibitor that went through several clinical trial investigations for advanced carcinomas (NCT00004147, NCT00003721, NCT00001683, and NCT00020683) (Fingleton 2003;Gu et al. 2005;Chu et al. 2007). Other MMP inhibitors include JNJ0966, with a high selectivity toward MMP-9 (Scannevin et al. 2017), and the antibody Fab 3,369 that targets MMP-14 (Ling et al. 2017). ...

Reference:

Cancer Stem Cells: Robust Features and Therapeutic Targets